Primsol
(Trimethoprim)ApprovedSmall molecule
Primsol is one of 137 small molecule programs targeting Acute bronchitis. It is currently in Approved.
6
Indications
16
Total Trials
2
Active Trials
136
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Cabometyx
Bristol-Myers SquibbPhase 3
Primsol
CConrado Roberto Hoffmann Filho
Approved
Glucophage
EMD SeronoPhase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Aglatimagene Besadenovec
CCandel Therapeutics, Inc.
Phase 3
Docetaxel /m²
AstraZenecaPhase 3
AAA817
NovartisPhase 3
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pneumonia2 trials
Acute bronchitis1 trial
10 more indications
Epidermolysis Bullosa1 trial
Interaction1 trial
Recurrent urinary tract infections1 trial
Antibiotic Prophylaxis1 trial
Type 1 Diabetes1 trial
Islet Transplantation for Type 1 Diabetes
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00014911·36 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
PROLOPRIM
NDA NDA017943
Jan 1, 1982
TRIMPEX
NDA NDA017952
Jul 30, 1982
TRIMETHOPRIM
NDA NDA018679
Jun 23, 1995
PRIMSOL
NDA NDA074374
Jan 24, 2000
PRIMSOL
NDA NDA074973
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trimethoprim. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- CConrado Roberto Hoffmann Filho